LAWRENCE, Mass., Oct. 16, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, celebrated the grand opening of its new headquarters in Lawrence, Massachusetts, in a special ceremony this week with Governor Deval Patrick and other local officials. The event, which included a formal ribbon-cutting ceremony, tour of NxStage's new headquarters at Riverwalk Properties in Lawrence and product demonstrations, took place Monday, October 15th. Speakers included Governor Deval Patrick, Congresswoman Niki Tsongas and NxStage Medical CEO Jeffrey Burbank.
As one of the largest and fastest growing medical device companies in Massachusetts, NxStage continues to contribute to the growth and vitality of the area. NxStage's new 137,000 square foot facility replaces its prior 58,000 square foot headquarters and houses the company's 300 employees within research and development, sales and marketing, customer and technical support and other functions. NxStage's new headquarters remains in Lawrence, Massachusetts, and is expected to accommodate the company's future growth.
"Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences," said Governor Patrick. "I congratulate NxStage on this significant achievement and for reaffirming its commitment to Massachusetts."
"As the leader in home hemodialysis, NxStage is revolutionizing renal care with innovative technologies including our System One™, which provides life-changing therapy to thousands of patients," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage Medical. "We are very appreciative that the Governor and others recognize the importance of what we're working to accomplish to ensure that this life-changing therapy option is available to all dialysis patients."
During the event, local officials and community members toured NxStage Medical's new facility, viewed demonstrations of innovative dialysis products and met with local patients and families who have benefitted from home hemodialysis with the NxStage System One.
"Being at home and in control of my treatment is what was important to me when I sought home hemodialysis therapy with NxStage," said NxStage dialyzor Richard Sicurella of Winthrop, Massachusetts, who attended the grand opening celebration. "But the health and quality of life benefits are what is helping me to live a good life, a life where my wife and I can enjoy our retirement and spend time together. I believe this would not be possible without NxStage. This therapy has changed my life."
Since its founding in 1998, NxStage has remained headquartered in Lawrence. The Company was named to Deloitte's Technology Fast 500 four years in a row, in 2008, 2009, 2010 and 2011. In 2008, NxStage Medical was named the fourth largest revenue gainer in Massachusetts by the Boston Business Journal and in 2009 was recognized as the third fastest growing company in Massachusetts. NxStage is a beneficiary of The Massachusetts Life Sciences Center, which seeks to promote and invest in the life sciences within the Commonwealth of Massachusetts.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq. VP, Investor Relations email@example.com
SOURCE NxStage Medical, Inc.